相关实验视频

Updated: Jun 25, 2026

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

静脉注射免疫球蛋白输液引起的血清 (1-3) -β-D-葡萄糖的动态变化:一项前性研究

Xixi Wan¹, Rong Liufu², Ruiting Liu²

¹Medical Intensive Care Unit, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China; Intensive Care Unit, The Second Hospital of Jiaxing, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, 314000, China.

Diagnostic microbiology and infectious disease

|June 1, 2024

概括

静脉注射免疫球蛋白 (IVIG) 输液可以增加患者的血清 (1-3) -β-D-葡萄糖 (BDG) 水平. 这些BDG的升高与IVIG产品有关.

科学领域:

临床化学临床化学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

血清 (1-3)-β-D-葡萄糖 (BDG) 是真菌感染的生物标志物.
静脉注射免疫球蛋白 (IVIG) 用于治疗各种自身免疫和炎症性疾病.
需要调查IVIG产品可能受到BDG的污染.

研究的目的:

为了研究IVIG输液后血清BDG水平的动态变化,成年患者.
为了确定IVIG产品BDG含量与血清BDG升高之间的相关性.
评估患者功能对血清BDG变化的影响IVIG后.

主要方法:

接受IVIG的住院患者的前性研究.
在注射前和注射后的9个时间点测量血清BDG水平.
使用弗里德曼测试和斯皮尔曼相关性进行统计分析.
基于功能BDG增量的比较.

主要成果:

与基线相比,IVIG输注后血清BDG水平显著增加.
血清BDG升高与IVIG产品中的BDG度相关.
患有功能异常的患者表现出较高的血清BDG增加.

结论:

输入IVIG导致血清BDG的显著增加.
血清BDG的升高与IVIG产品的BDG含量有关.
异常的功能可能会加剧IVIG后BDG水平的变化.

关键词:

(1-3) -β - 葡萄糖的使用.动态变化动态变化这是错误的阳性.真菌感染的真菌感染.静脉内注射的免疫球蛋白是什么

更多相关视频

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma

Published on: June 2, 2023

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...